The size threshold that separates OATS from OCA

The most practical question when osteochondral transplantation comes up is straightforward: how large is the defect? A working threshold of roughly 2–4 cm² acts as the primary clinical gate. Below it, OATS (osteochondral autograft transfer) is generally the first-line osteochondral transplantation option for active, otherwise healthy patients who have already tried and not been helped by conservative treatment. Above it, OCA — osteochondral allograft transplantation using fresh cadaveric tissue — is typically preferred.

The reason comes down to supply. In OATS, cylindrical plugs of bone and cartilage are harvested from the patient's own knee, from areas that bear little weight during everyday movement. That supply is finite. As defect area grows, the available donor material runs out before the recipient site is adequately covered, and residual gaps tend to fill with fibrocartilage rather than the hyaline cartilage the procedure aims to restore — a meaningful difference in repair quality. OCA sidesteps this constraint entirely by drawing on a tissue-banked donor, enabling treatment of lesions spanning 1 to nearly 14 cm² in reported series.

Both procedures are single-stage, and neither is inherently superior — each is the right tool for a different defect size. The 2–4 cm² threshold is a clinical guide rather than a hard rule, and a genuine grey zone exists where the two options overlap; that nuance is explored later in the article.

Why OATS suits smaller, contained defects

Harvesting from the patient's own knee is what gives OATS its characteristic logic. A surgeon removes one or more cylindrical cores of bone and cartilage — typically from the superolateral trochlea or the perinotch region, both areas that bear little load during normal movement — and presses them into the prepared defect site. Because the graft is the patient's own tissue, there is no risk of immune rejection or disease transmission.

The size window for this technique is relatively narrow. Contemporary arthroscopic OATS series consistently exclude defects larger than 20 mm in diameter, and the median treated defect in recent knee studies is 7–10 mm — a useful guide for patients trying to picture where their lesion sits within the treatable range. In surface-area terms, OATS is generally suited to defects of 1–2 cm²; the mosaicplasty variant, which tiles multiple smaller plugs across the recipient site, can extend coverage to roughly 4 cm², though this approach reaches its own practical ceiling before very large defects are addressed, for the supply reasons set out in the previous section. For talar applications, the threshold works differently: published inclusion criteria place the minimum treatable defect at greater than 5 mm, reflecting that smaller lesions may respond adequately to conservative management alone.

Patient selection matters as much as defect size. OATS is generally reserved for active patients who remain symptomatic after conservative treatment has been tried. Relative contraindications include a BMI above 40, age over 50, and Kellgren-Lawrence grade 2 or higher osteoarthritis — all of which affect the mechanical environment into which the graft must integrate.

When OCA becomes the preferred option

Once defect area pushes past the practical ceiling of autograft supply, OCA steps in as the preferred osteochondral option. The scale advantage becomes most apparent at the complex end of the spectrum: reconstructions for large bipolar lesions — where cartilage loss affects both opposing joint surfaces simultaneously — average 16.7 cm² of treated area, a figure simply beyond the reach of any autograft harvest. Because OCA draws on fresh cadaveric donor tissue, the surgeon is not constrained by how much the patient's own knee can donate.

Two clinical scenarios in particular favour OCA over OATS. The first is precisely that bipolar presentation: when both articulating surfaces are damaged, autograft volume is insufficient to address both sides without creating unacceptable donor-site harm. The second is the combination of osteochondral damage and meniscal deficiency. When these two problems coexist, combined OCA plus meniscal allograft transplantation (MAT) is generally preferred over OATS. A systematic review of 188 patients with a mean age of 32.4 years who underwent OCA and MAT found significant improvements across all patient-reported outcome scores, with 82–90% reporting they would choose the procedure again.

A common misconception is that using donor tissue implies a more complicated, multi-stage operation. It does not. OCA is carried out in a single procedure — the same number of surgical steps as OATS. The practical difference is where the graft comes from, not how many times a patient goes to theatre.

What the donor source means for risk and logistics

Cadaveric graft, sourced from an unknown donor and processed through a tissue bank, understandably prompts a practical concern: how safe is it? A cohort study of 372 patients followed for a mean of 5.4 years provides a reassuring answer on at least one dimension — donor sex, age, and graft storage duration did not independently predict clinical failure or outcomes when recipient variables were accounted for. The characteristics of the donor appear less decisive than those of the patient receiving the graft.

One finding in that dataset can look alarming without context. Female OCA recipients had a 90% rate of donor–recipient sex mismatch — a striking figure, but one that reflects anatomy rather than immune response. Male and female femoral condyles differ in geometry, so size-matched grafts for female recipients more often come from male donors. The higher rate of tibial tubercle osteotomy in the same group — a procedure for correcting patellofemoral mechanics — confirms that what surgeons are navigating here is anatomical fit, not biological incompatibility.

The logistical contrast with OATS is nevertheless real. OATS draws graft from the patient's own knee during the same operation: no tissue bank, no size-matching process, no cold-storage window to coordinate. OCA requires a fresh cadaveric graft to be identified, anatomy-matched, and used within its storage period — steps that add coordination before surgery that autograft avoids entirely.

This means the two procedures carry genuinely different, rather than clearly unequal, risk profiles: autograft centres the question on the long-term behaviour of the harvest site within the patient's own knee — an outcome where published evidence thins considerably beyond the short-to-mid-term — while allograft centres it on how reliably a fresh but external tissue integrates.

Survivorship and return-to-sport rates

Return to activity is often the number patients most want to know. After focal OCA, published series put the rate at approximately 75% back in sport or recreation by six years; among competitive athletes, 84% returned to an equal or higher competitive level at around 11 months post-surgery. These figures are population averages — individual outcomes vary with defect location, prior surgery history, and overall joint health.

Longer-term graft survival for focal OCA runs at approximately 83% at five years and 70% at ten years. In one extended series, 68% of grafts remained in place and functioning at a mean of nearly 13 years — providing reasonable reassurance that a meaningful proportion achieve genuine longevity rather than simply deferring the problem.

Defect complexity noticeably shifts those benchmarks. For large bipolar lesions — where both opposing joint surfaces are affected, with a mean treated area of 16.7 cm² — survivorship falls to approximately 74% at five years and 59% at fifteen years. Morphology and extent of damage, not size alone, modulate prognosis.

Both procedures may benefit from bone marrow aspirate concentrate (BMAC — a biological preparation drawn from the patient's own bone marrow that supports tissue integration). For OCA, one prospective study found BMAC augmentation cut the reoperation rate from 35% to 5%. For OATS, adding BMAC alongside a twelve-week rehabilitation programme raised MOCART 2.0 scores — an MRI-based cartilage quality measure rated 0 to 100, where higher is better — from 71.7 on a shorter unsupplemented protocol to 96.1. Both biological support and rehabilitation length appear to matter; neither factor was sufficient on its own.

On durability, a ten-year comparison against microfracture (the Gudas 2012 series) provides the clearest published evidence that OATS maintains hyaline-quality repair over time — an advantage that simpler marrow-stimulation techniques do not consistently sustain.

When the two procedures genuinely overlap

Around 2–4 cm², the tidy size-based rule quietly dissolves. A 3 cm² defect on the medial femoral condyle with an intact meniscus and well-aligned limb sits in territory where OATS mosaicplasty, OCA, and MACI can all be argued on reasonable grounds. The SUMMIT trial data suggest MACI outperforms microfracture for defects of 3 cm² or above, but that does not establish superiority over osteochondral transfer. Head-to-head RCT evidence directly comparing OCA and OATS remains sparse; most guidance at this threshold rests on cohort studies and expert consensus rather than controlled trials.

What often resolves the ambiguity is concurrent pathology rather than size alone. Take the same 3 cm² defect alongside meniscal loss: the combination tips the decision decisively toward OCA paired with meniscal allograft transplantation, a strategy cohort evidence supports over autograft in that setting. Prior marrow stimulation, subchondral bone loss, malalignment, and the patient's realistic activity demands can each shift the calculus further — sometimes more sharply than a few millimetres of defect area.

The honest takeaway from the evidence is that decisions in this range require a surgeon experienced across the full osteochondral toolkit: someone able to weigh defect geometry, the condition of surrounding tissue, and the patient's functional goals together. That judgement cannot be reduced to a threshold. Seeking a consultation with a clinician who regularly performs both OATS and OCA — and who can compare them honestly — is the most useful next step for anyone whose defect falls in this range.